On Monday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: U.S. Silica Holdings (NYSE:SLCA), Synta Pharmaceuticals (NASDAQ:SNTA), McDermott International (NYSE:MDR), Companhia Siderurgica Nacional (NYSE:SID)
23 hours ago U.S. Silica Holdings Inc (NYSE:SLCA) will meet with investors on March 25, 2015 at the BB&T Capital Markets 9th Annual Commercial and Industrial Conference, at the Biltmore Hotel in Coral Gables, Florida.
U.S. Silica Holdings Inc (NYSE:SLCA) enhanced 3.93%, and closed at $32.76. The company holds the market capitalization of $1.75 billion. For the last twelve months, the stock was able to keep return on equity at 37.90%, while return on assets at 13.60%, in response to its return on investment at 15.30%. Its 20-day moving average gained 5.97%, below 50-day moving average of 13.88%, below 200-day moving average of -26.62% from the latest market price of $32.76. The mean recommendation of analysts for this stock is 2.10. (Where 1=Buy, 5=Sale).
U.S. Silica Holdings Inc (SLCA) produces and sells commercial silica in the United States. It operates through two segments, Oil & Gas Proppants, and Industrial & Specialty Products. The corporation offers whole grain commercial silica products to be used as fracturing sand in connection with oil and natural gas recovery, in addition to sells its whole grain silica products in various size distributions, grain shapes, and chemical purity levels for manufacturing glass products.
Formerly on 12 March 2015 Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stated financial results for the fourth quarter and year ended December 31, 2014 and offered an operational update.
Final Results from GALAXY-1 Stated; GALAXY-2 Clinical Trial Remains on Track for Interim Analysis of Overall Survival in 2015. In 2014, Synta declared final results from the global, randomized, multi-center Phase 2b GALAXY-1 study comparing the combination of ganetespib and docetaxel to docetaxel alone for the second-line treatment of advanced non-small cell adenocarcinoma. The final results from this trial, in particular the encouraging overall survival results and tolerability profile in patients whose time from diagnosis of advanced disease is greater than 6 months, support the selection of this population for the ongoing pivotal Phase 3 GALAXY-2 trial.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA)’s shares picked up 4.03%, and closed at $2.58. The stock volatility for the week is 7.19%, while for the month remained 6.24%. The company holds consensus target price of $8.75.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.89 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 31.50% and Annual EPS growth for the past 5 years is considered as -18.90%.
The mean recommendation of analysts for this stock is 2.70. (Where 1=Buy, 5=Sale).
Synta Pharmaceuticals Corp. (SNTA) a biopharmaceutical corporation focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, counting cancer and chronic inflammatory diseases.
McDermott International (NYSE:MDR) inclined 3.49%, and closed at $3.42. The company has the market capitalization of $813.31 million. The beta value of the stock is 2.16. On the other hand the stock’s volatility for the week is 5.42%, and for the month is 6.01%. The stock’s price to book ratio is $0.54, however price to sale ratio is $0.35. Analyst’s mean recommendation regarding this stock is 3.00. (Where 1=Buy, 5=Sale).
McDermott International (MDR) works as an engineering, procurement, construction, and installation corporation worldwide. The corporation operates through three segments: Asia Pacific, Americas, and the Middle East. It focuses on designing and executing offshore oil and gas projects.
Formerly On March 12, 2015 Companhia Siderurgica Nacional (ADR) (NYSE:SID) uncovers its results for the fourth quarter (4Q14) and the fiscal year of 2014: Fourth-quarter adjusted EBITDA amounted to R$1.0 billion, 3% higher than in 3Q14, largely due to the steel segment, while the adjusted EBITDA margin widened by 2 p.p. to 25% in the same period.
In 2014, adjusted steel segment EBITDA came to R$2.9 billion, 20% up on the year before, accompanied by an adjusted EBITDA margin of 26%, growth of 6 p.p. over 2013;
yearly iron ore sales volume totaled 29 million tonnes, 13% more than in the previous year, while iron ore shipped through Tecar reached a record 33 million tonnes, 14% up in the same period;
Companhia Siderurgica Nacional (ADR) (NYSE:SID) rose 3.93%, and closed at $1.85. The stock has the beta value of 1.81, and its volatility for the week is 4.84%, while for the month it is 4.73%. The company has the market capitalization of $2.62 billion. The company holds the book value per share of 1.29. Price to book ratio remained 1.43, while price to sale ratio is 0.50. Analysts mean recommendation for the stock is said to be 3.80 (where 1=Buy, 5=sale).
Companhia Siderurgica Nacional (ADR) (SID) works as an integrated steel producer primarily in Brazil. It operates through five segments: Steel, Mining, Cement, Logistics, and Energy. The corporation primarily produces carbon steel and various steel products for automotive, home appliance, packaging, construction, and steel processing industries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
